🟢 Neumora Therapeutics is trading 5.41% up in pre-market; no clear company-specific catalyst reported

Neumora Therapeutics is trading at $1.56 (+5.41%), with no clearly reported company-specific catalyst for August 28, 2026.

• Recent coverage includes August 14 second-quarter results and favorable NMRA-215 toxicology data, but both predate this move.
• Insider-sale reports updated August 28 cover transactions from August 20–21 and provide no direct explanation for the pre-market gain.
• Major U.S. indexes are nearly flat, offering limited broader-market support.